CooperCompanies to acquire Generate Life Sciences for $1.6B cash, expected to close Q1 2022

COOPER COMPANIES, INC.

CooperSurgical unit will acquire Generate, a provider of donor egg/sperm, fertility cryopreservation, and newborn stem cell storage.
Aggregate cash consideration of $1.605 billion; transaction not subject to financing condition.
Generate reported trailing twelve-month revenue of ~$250M as of Sep 30, 2021.
Deal expected to be accretive to non-GAAP EPS by ~$0.30 in first year after closing, excluding one-time and amortization charges.
Closing anticipated in Cooper's first fiscal quarter of 2022 (starting Nov 1), subject to HSR and customary conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.